As the program engages more directly with global concerns such as the climate crisis, he will lead the way.

T-cell engager (TCE) specialist Candid Therapeutics has entered a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s rare disease maternal ...